25.5. Analysis.
Comparison 25: VX‐659 (400 mg once daily) plus tezacaftor (100 mg once daily) plus deutivacaftor (150 mg once daily) versus placebo (F508del/MF), Outcome 5: Sweat chloride (change from baseline) (mmol/L)
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.